ArticleMolecular biology reports2026
Integrated in vitro and in silico analysis of pomegranate-derived polyphenols targeting novel variants in MCF-7 breast cancer cells.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer remains an important health burden among people of different geographical regions worldwide, with a recorded number of cases diagnosed at approximately 2.3 million in the year 2022.
methodsThis research employed both experimental and computational methods to investigate the potential of treating ER-positive breast cancer using MCF-7 cell lines with three pomegranate-derived compounds (polyphenols), specifically ellagic acid, gallic acid, and punicalagin.
resultsWhole-genome sequencing of MCF-7 cells revealed key mutated genes as ESR1, EYA3, LYST, GATA3, and SLC39A12, critically involved in the pathogenesis of breast cancer. Results from in vitro studies showed that each of the compounds demonstrated both time- and dose-dependent decreases in cell viability, induced by apoptosis, as well as increases in caspase activation and reactive oxygen species levels. DISCUSSION: Significant binding affinities and interactions have been identified for ESR1, EYA3, and LYST proteins. Further elucidation of the potential mechanisms by which pomegranate components modify cancer-related pathways was performed using network analysis and pathway enrichment.
conclusionThis study provides scientific evidence for the components of pomegranate juice and their strategies for preventing and treating breast cancer, bridging the gap between traditional knowledge and modern evidence-based medicine.
Indexed as
Identifiers
41894070What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.